BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34855399)

  • 1. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
    Yu X; Xu J; Xie L; Wang L; Shen Y; Cahuzac KM; Chen X; Liu J; Parsons RE; Jin J
    J Med Chem; 2021 Dec; 64(24):18054-18081. PubMed ID: 34855399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
    Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
    J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.
    You I; Erickson EC; Donovan KA; Eleuteri NA; Fischer ES; Gray NS; Toker A
    Cell Chem Biol; 2020 Jan; 27(1):66-73.e7. PubMed ID: 31859249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress towards clinically relevant ATP-competitive Akt inhibitors.
    Huck BR; Mochalkin I
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2838-2848. PubMed ID: 28506751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
    Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
    ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
    Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
    J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
    Blake JF; Xu R; Bencsik JR; Xiao D; Kallan NC; Schlachter S; Mitchell IS; Spencer KL; Banka AL; Wallace EM; Gloor SL; Martinson M; Woessner RD; Vigers GP; Brandhuber BJ; Liang J; Safina BS; Li J; Zhang B; Chabot C; Do S; Lee L; Oeh J; Sampath D; Lee BB; Lin K; Liederer BM; Skelton NJ
    J Med Chem; 2012 Sep; 55(18):8110-27. PubMed ID: 22934575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
    J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt Pathway Inhibitors.
    Uko NE; Güner OF; Matesic DF; Bowen JP
    Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader.
    Zhu CL; Luo X; Tian T; Rao Z; Wang H; Zhou Z; Mi T; Chen D; Xu Y; Wu Y; Che J; Zhou Y; Li J; Dong X
    Eur J Med Chem; 2022 Aug; 238():114459. PubMed ID: 35635954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
    Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
    J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
    Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
    Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
    Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
    Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.